12.85

1.68% -0.22

After Hours: 12.85

Oculis Holding AG (OCS)

Overview News Price History Discussions Forecast

Oculis Holding AG stock is currently priced at $12.85, with a 24-hour trading volume of 43,235. It has seen a -1.68% decreased in the last 24 hours and a +10.59% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $12.98 pivot point. If it approaches the $12.67 support level, significant changes may occur.

Previous Close:

$13.07

Open:

$13

24h Volume:

43,235

Market Cap:

$535.20M

Revenue:

Net Income/Loss:

$-57.69M

P/E Ratio:

-9.0493

EPS:

-1.42

Net Cash Flow:

$-113.32M

1W Performance:

+7.26%

1M Performance:

+10.59%

6M Performance:

+41.21%

1Y Performance:

+1.90%

1D Range:

$12.10

$13.00

52W Range:

$9.05

$14.50

Oculis Holding AG Stock (OCS) Company Profile

Name

Oculis Holding AG

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

41 58 810 0182

Address

Bahnhofstrasse 7, Zug

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OCS's Discussions on Twitter

Oculis Holding AG Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

Oculis Holding AG Stock (OCS) Latest News

Oculis Publishes Invitation to the Annual General Meeting

GlobeNewswire Inc.

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

GlobeNewswire Inc.

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

GlobeNewswire Inc.

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

GlobeNewswire Inc.

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

GlobeNewswire Inc.

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

GlobeNewswire Inc.

Oculis Holding AG Stock (OCS) Financials Data

Oculis Holding AG (OCS) Net Income 2024

OCS net income (TTM) was -$57.69 million for the quarter ending December 31, 2023, a -67.05% decrease year-over-year.

Oculis Holding AG (OCS) Cash Flow 2024

OCS recorded a free cash flow (TTM) of -$113.32 million for the quarter ending September 30, 2023.

Oculis Holding AG (OCS) Earnings per Share 2024

OCS earnings per share (TTM) was -$1.6427 for the quarter ending December 31, 2023, a -55.71% decline year-over-year.

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.